Mycophenolic acid response biomarkers: A cell line model system-based genome-wide screen

International Immunopharmacology

Volumn 11, Issue 8, 2011, Pages 1057-1064

  Wu, Tse Yu ^a   Fridley, Brooke L ^a   Jenkins, Gregory D ^a   Batzler, Anthony ^a   Wang, Liewei ^a   Weinshilboum, Richard M ^a  

^a MAYO CLINIC   (United States)

Author keywords

C17orf108; CYPRD1; Mycophenolic acid; NASP; Pharmacogenomics; RRM2

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; MYCOPHENOLIC ACID; SMALL INTERFERING RNA;

AREA UNDER THE CURVE; ARTICLE; C17ORF108 GENE; CONTROLLED STUDY; CYBRD1 GENE; CYTOTOXICITY; FOLLOW UP; GENE; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; NASP GENE; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; RRM2 GENE;

EID: 84860389864     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2011.02.027     Document Type: Article

References (44)

1. HRSA. Annual report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1998-2007.
2. U.S. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation. Rockville: MD; 2008.
3. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1996;61: 1029-37.
4. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995;60:225-32.
5. Hiemstra TF, Jones RB, Jayne DR. Treatment of primary systemic vasculitis with the inosine monophosphate dehydrogenase inhibitor mycophenolic acid. Nephron Clin Pract 2010;116:c1-c10.
6. Mak A, Cheak AA, Tan JY, Su HC, Ho RC, Lau CS. Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression. RheumatologyOxford 2009;48:944-52.
7. Takebe N, Cheng X, Wu S, Bauer K, Goloubeva OG, Fenton RG, et al. Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients. Clin Cancer Res 2004;10:8301-8. (Pubitemid 40053390)
8. Wu JC. Mycophenolate mofetil: molecular mechanisms of action. Perspect Drug Discovery Des 1994;2:185-204.
9. Allison AC, Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 2005;80: S181-90. (Pubitemid 41552905)
10. Villarroel MC, Hidalgo M, Jimeno A. Mycophenolate mofetil: an update. Drugs Today Barc 2009;45:521-32.
11. Barraclough KA, Lee KJ, Staatz CE. Pharmacogenetic influences on mycophenolate therapy. Pharmacogenomics 2010;11:369-90.
12. Shipkova M, Armstrong VW, Wieland E, Niedmann PD, Schutz E, Brenner-Weiss G, et al. Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br J Pharmacol 1999;126:1075-82. (Pubitemid 29123740)
13. Fernandez A, Martins J, Villlafruela JJ, Marcen R, Pascual J, Cano T, et al. Variability of mycophenolate mofetil trough levels in stable kidney transplant patients. Transplant Proc 2007;39:2185-6. (Pubitemid 47418137)
14. Pisupati J, Jain A, Burckart G, Hamad I, Zuckerman S, Fung J, et al. Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients. J Clin Pharmacol 2005;45:34-41.
15. Levesque E, Delage R, Benoit-Biancamano MO, Caron P, Bernard O, Couture F, et al. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Clin Pharmacol Ther 2007;81:392-400. (Pubitemid 46364482)
16. Le Meur Y, Buchler M, Thierry A, Caillard S, Villemain F, Lavaud S, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007;7:2496-503. (Pubitemid 47566324)
17. Weber LT, Shipkova M, Armstrong VW, Wagner N, Schutz E, Mehls O, et al. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol 2002;13:759-68. (Pubitemid 34183943)
18. Barraclough KA, Staatz CE, Isbel NM, Johnson DW. Therapeutic monitoring of mycophenolate in transplantation: is it justified? Curr Drug Metab 2009;10: 179-87.
19. Knight SR, Morris PJ. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation 2008;85:1675-85.
20. Glander P, Braun KP, Hambach P, Bauer S, Mai I, Roots I, et al. Non-radioactive determination of inosine 5'-monophosphate dehydro-genase (IMPDH) in peripheral mononuclear cells. Clin Biochem 2001;34:543-9. (Pubitemid 34014847)
21. Glander P, Hambach P, Braun KP, Fritsche L, Giessing M, Mai I, et al. Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am J Transplant 2004;4:2045-51. (Pubitemid 39611633)
22. Sanquer S, Breil M, Baron C, Dhamane D, Astier A, Lang P. Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil. Clin Pharmacol Ther 1999;65:640-8. (Pubitemid 29294027)
23. Sombogaard F, van Schaik RH, Mathot RA, Budde K, van der Werf M, Vulto AG, et al. Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757 TNC polymorphism. Pharmacogenet Genomics 2009;19:626-34.
24. Wang J, Yang JW, Zeevi A, Webber SA, Girnita DM, Selby R, et al. IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients. Clin Pharmacol Ther 2008;83:711-7. (Pubitemid 351556015)
25. Wang J, Zeevi A, Webber S, Girnita DM, Addonizio L, Selby R, et al. A novel variant L263F in human inosine 5'-monophosphate dehydrogenase 2 is associated with diminished enzyme activity. Pharmacogenet Genomics 2007;17:283-90. (Pubitemid 46668052)
26. Winnicki W, Weigel G, Sunder-Plassmann G, Bajari T, Winter B, Herkner H, et al. An inosine 5'-monophosphate dehydrogenase 2 single-nucleotide polymorphism impairs the effect of mycophenolic acid. Pharmacogenomics J 2010;10:70-6.
27. Gensburger O, Van Schaik RH, Picard N, Le Meur Y, Rousseau A, Woillard JB, et al. Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil. Pharmacogenet Genomics.20:537-43.
28. Glander P, Budde K. Target enzyme activity as a biomarker for immunosuppression. Ther Drug Monit 2010;32:257-60.
29. Li L, Fridley B, Kalari K, Jenkins G, Batzler A, Safgren S, et al. Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression. Cancer Res 2008;68:7050-8.
30. Niu N, Qin Y, Fridley BL, Hou J, Kalari KR, Zhu M, et al. Radiation pharmacogenomics: a genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines. Genome Res 2010;20: 1482-92.
31. Li L, Fridley BL, Kalari K, Jenkins G, Batzler A, Weinshilboum RM, et al. Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers. PLoS ONE 2009;4:e7765.
32. Wu ZJ, Irizarry RA, Gentleman R, Martinez-Murillo F, Spencer F. A model-based background adjustment for oligonucleotide expression arrays. J Am Stat Assoc 2004;99:909-17. (Pubitemid 39665934)
33. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA 2003;100:9440-5. (Pubitemid 37033947)
34. Bleibel WK, Duan S, Huang RS, Kistner EO, Shukla SJ, Wu X, et al. Identification of genomic regions contributing to etoposide-induced cytotoxicity. Hum Genet 2009;125:173-80.
35. Huang RS, Duan S, Kistner EO, Hartford CM, Dolan ME. Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans. Mol Cancer Ther 2008;7:3038-46.
36. Sie L, Loong S, Tan EK. Utility of lymphoblastoid cell lines. J Neurosci Res 2009;87: 1953-9.
37. Choy E, Yelensky R, Bonakdar S, Plenge RM, Saxena R, De Jager PL, et al. Genetic analysis of human traits in vitro: drug response and gene expression in lymphoblastoid cell lines. PLoS Genet 2008;4:e1000287.
38. Jordan A, Reichard P. Ribonucleotide reductases. Annu Rev Biochem1998;67:71-98. (Pubitemid 28411124)
39. Cerqueira NM, Fernandes PA, Ramos MJ. Ribonucleotide reductase: a critical enzyme for cancer chemotherapy and antiviral agents. Recent Pat Anticancer Drug Discov 2007;2:11-29. (Pubitemid 46723151)
40. Wyman S, Simpson RJ, McKie AT, Sharp PA. Dcytb (Cybrd1) functions as both a ferric and a cupric reductase in vitro. FEBS Lett 2008;582:1901-6.
41. Latunde-Dada GO, Simpson RJ, McKie AT. Duodenal cytochrome B expression stimulates iron uptake by human intestinal epithelial cells. J Nutr 2008;138: 991-5. (Pubitemid 351769119)
42. Osakabe A, Tachiwana H, Matsunaga T, Shiga T, Nozawa RS, Obuse C, et al. Nucleosome formation activity of human somatic nuclear autoantigenic sperm protein (sNASP). J Biol Chem 2010;285:11913-21.
43. Richardson RT, Alekseev OM, Grossman G, Widgren EE, Thresher R, Wagner EJ, et al. Nuclear autoantigenic sperm protein (NASP), a linker histone chaperone that is required for cell proliferation. J Biol Chem 2006;281:21526-34. (Pubitemid 44115489)
44. Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, et al. Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet 2004;36:40-5. (Pubitemid 38056206)